Immune-mediated diseases comprise a clinically heterogeneous group of diseases affecting about 5% of individuals of European origin. Knowledge of their pathogenic mechanisms has strikingly increased these recent years taking advantage of the huge progresses made in immunogenetics.
Our research offers a unique opportunity both in basic and in translational approaches to continue the deciphering of immunogenic disorders. Our goal is to link inflammation and immune system with human diseases based on a multidisciplinary approach which involves a two-way process going back and forth between the analysis of the genetic data, the dissection of immunological mechanisms and the potential transfer of the findings to the patient management.
Our main research interest is to decipher the molecular mechanisms leading to the establishment of immune tolerance to self and therefore preventing autoimmune manifestations and diseases.
Three main pillars constitute the organization of the research program within the team: 1) regulation of auto-antigen expression, 2) Genomic analysis of the immune mediated disease with diagnostic, prognostic and therapeutic applications, 3) Functional validation of raised pathways using in vitro and animal models.
Our ultimate goal is to help development of new diagnostic and therapeutic strategies based on pathophysiological grounds. The interactions between scientists and physicians in the team contribute importantly to the translation of fundamental research into clinical application.
- Giraud M, Taubert R, Vandiedonck C, Ke X, Lévi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus.Nature. 2007 Aug 23;448(7156):934-7.
- Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, Colonna M, Bernhardt G, Kahan A, Chiocchia G, Distler JH, Allanore Y.Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis. 2013 Jun;72(6):1089-98.
- Koumakis E, Giraud M, Dieudé P, Cohignac V, Cuomo G, Airò P, Hachulla E, Matucci-Cerinic M, Diot E, Caramaschi P, Mouthon L, Riccieri V, Cracowski JL, Tiev KP, Francès C, Amoura Z, Sibilia J, Cosnes A, Carpentier P, Valentini G, Manetti M, Guiducci S, Meyer O, Kahan A, Boileau C, Chiocchia G, Allanore Y.Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum. 2012 Aug;64(8):2746-52.
- Allanore Y, Saad M, Dieudé P, Avouac J, Distler JH, Amouyel P, Matucci-Cerinic M, Riemekasten G, Airo P, Melchers I, Hachulla E, Cusi D, Wichmann HE, Wipff J, Lambert JC, Hunzelmann N, Tiev K, Caramaschi P, Diot E, Kowal-Bielecka O, Valentini G, Mouthon L, Czirják L, Damjanov N, Salvi E, Conti C, Müller M, Müller-Ladner U, Riccieri V, Ruiz B, Cracowski JL, Letenneur L, Dupuy AM, Meyer O, Kahan A, Munnich A, Boileau C, Martinez M. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011 Jul;7(7):e1002091.
- The Allanore lab received an Atip/Avenir Grant from the French government [Jan 2013]
- The The Giraud lab received «Chair of Excellence» Grant from the French government [Jul 2011]